Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
US11518764B2 · kind B2 · utility
2Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 6, 2019 |
| Grant date | Dec 6, 2022 |
| Priority date | — |
| Expiry date | Apr 17, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.